127 related articles for article (PubMed ID: 11245336)
21. Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: an immunohistochemical study.
Godge PY; Poonja LS
Indian J Dent Res; 2011; 22(3):493-4. PubMed ID: 22048598
[TBL] [Abstract][Full Text] [Related]
22. CD44 loss in gastric stromal tumors as a prognostic marker.
Montgomery E; Abraham SC; Fisher C; Deasel MR; Amr SS; Sheikh SS; House M; Lilliemoe K; Choti M; Brock M; Ephron DT; Zahuruk M; Chadburn A
Am J Surg Pathol; 2004 Feb; 28(2):168-77. PubMed ID: 15043305
[TBL] [Abstract][Full Text] [Related]
23. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer.
Dall P; Heider KH; Sinn HP; Skroch-Angel P; Adolf G; Kaufmann M; Herrlich P; Ponta H
Int J Cancer; 1995 Feb; 60(4):471-7. PubMed ID: 7530237
[TBL] [Abstract][Full Text] [Related]
24. Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors.
Granberg D; Wilander E; Oberg K; Skogseid B
Int J Cancer; 1999 Oct; 84(5):484-88. PubMed ID: 10502723
[TBL] [Abstract][Full Text] [Related]
25. Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy.
Kallakury BV; Yang F; Figge J; Smith KE; Kausik SJ; Tacy NJ; Fisher HA; Kaufman R; Figge H; Ross JS
Cancer; 1996 Oct; 78(7):1461-9. PubMed ID: 8839552
[TBL] [Abstract][Full Text] [Related]
26. Soluble CD44 isoforms in serum as potential markers of metastatic gastric carcinoma.
Harn HJ; Ho LI; Shyu RY; Yuan JS; Lin FG; Young TH; Liu CA; Tang HS; Lee WH
J Clin Gastroenterol; 1996 Mar; 22(2):107-10. PubMed ID: 8742647
[TBL] [Abstract][Full Text] [Related]
27. [Expression of CD44 and isoforms v4, v5, v6, v7, v10--new prognostic parameters in ductal pancreatic carcinoma?].
Böttger T; Maschek H; Gottwald W; Lobo M; Brenner W; Junginger T
Chirurg; 1998 Oct; 69(10):1089-92. PubMed ID: 9833191
[TBL] [Abstract][Full Text] [Related]
28. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study.
Ashida K; Terada T; Kitamura Y; Kaibara N
Hepatology; 1998 Apr; 27(4):974-82. PubMed ID: 9537436
[TBL] [Abstract][Full Text] [Related]
29. [Expression of CD44 variant v6 in breast carcinoma and its relationship with other parameters of tumor biology].
Aceituno E; Turrión F; San Román JM; Sarasa JL; Ortiz F; García R
Med Clin (Barc); 1998 Jul; 111(5):168-71. PubMed ID: 9732832
[TBL] [Abstract][Full Text] [Related]
30. CD44-9v and CD44-10v are potential molecular markers for squamous cell carcinoma of the vulva.
Rodríguez-Rodríguez L; Sancho-Torres I; Gibbon DG; Watelet LF; Mesonero C
J Soc Gynecol Investig; 2000; 7(1):70-5. PubMed ID: 10732319
[TBL] [Abstract][Full Text] [Related]
31. Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.
Pupa SM; Bufalino R; Invernizzi AM; Andreola S; Rilke F; Lombardi L; Colnaghi MI; Ménard S
J Clin Oncol; 1996 Jan; 14(1):85-94. PubMed ID: 8558226
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of adhesion molecule CD44 splice variants in lymph node metastases of cervical cancer.
Kainz C; Tempfer C; Kohlberger P; Janisch S; Koelbl H; Gitsch G; Breitenecker G
Int J Cancer; 1996 Jun; 69(3):170-3. PubMed ID: 8682582
[TBL] [Abstract][Full Text] [Related]
33. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study.
Shah NG; Trivedi TI; Vora HH; Patel KC; Tankshali R; Goswami JV; Shukla SN; Shah PM
Tumori; 2010; 96(6):971-7. PubMed ID: 21388061
[TBL] [Abstract][Full Text] [Related]
34. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
[TBL] [Abstract][Full Text] [Related]
35. Expression of CD44 isoforms in human renal cell carcinomas.
Heider KH; Ratschek M; Zatloukal K; Adolf GR
Virchows Arch; 1996 Jul; 428(4-5):267-73. PubMed ID: 8764936
[TBL] [Abstract][Full Text] [Related]
36. The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma.
Kunimura T; Yoshida T; Sugiyama T; Morohoshi T
J Gastrointest Cancer; 2009; 40(3-4):115-8. PubMed ID: 19937401
[TBL] [Abstract][Full Text] [Related]
37. Expression of CD44(v5-10) splicing variants in primary ovarian cancer and lymph node metastases.
Schröder W; Rudlowski C; Biesterfeld S; Knobloch C; Hauptmann S; Rath W
Anticancer Res; 1999; 19(5B):3901-6. PubMed ID: 10628329
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of CD44 variant expression in primary breast cancer.
Foekens JA; Dall P; Klijn JG; Skroch-Angel P; Claassen CJ; Look MP; Ponta H; Van Putten WL; Herrlich P; Henzen-Logmans SC
Int J Cancer; 1999 Jun; 84(3):209-15. PubMed ID: 10371335
[TBL] [Abstract][Full Text] [Related]
39. CD44 variant exon epitopes in primary breast cancer and length of survival.
Kaufmann M; Heider KH; Sinn HP; von Minckwitz G; Ponta H; Herrlich P
Lancet; 1995 Mar; 345(8950):615-9. PubMed ID: 7534855
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of CD44 standard, variant isoforms 3 and 6 and -catenin expression in local prostate cancer treated by radical prostatectomy.
Aaltomaa S; Lipponen P; Viitanen J; Kankkunen JP; Ala-Opas M; Kosma VM
Eur Urol; 2000 Nov; 38(5):555-62. PubMed ID: 11096236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
